Hikma Pharmaceuticals Stock Rating Reaffirmed by Morgan Stanley (HIK)
Hikma Pharmaceuticals (LON: HIK)‘s stock had its “overweight” rating restated by equities researchers at Morgan Stanley in a report issued on Tuesday. They currently have a $16.16 (1070 GBX) target price on the stock.
Hikma Pharmaceuticals (LON: HIK) opened at 1012.00 on Tuesday. Hikma Pharmaceuticals has a 52-week low of GBX 598.50 and a 52-week high of GBX 1009.00. The stock’s 50-day moving average is currently GBX 728.8. The company’s market cap is £1.991 billion.
A number of other analysts have also recently weighed in on HIK. Analysts at Jefferies Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note to investors on Wednesday, March 13th. They now have a $13.60 price target on the stock.
One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $14.96 (991 GBX).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.